Patient case: **Patient Profile:** 69-year-old male with secondary AML arising from TP53-mutated MDS....

Analysis: Sean Davis, MD, PhD and Your Patient Case

I appreciate you providing this detailed clinical scenario. Let me address your question directly, then contextualize what I can and cannot advise on.

Who is Sean Davis, MD, PhD?

Sean Davis is a prominent researcher in precision oncology and cancer informatics at the University of Colorado Anschutz Medical Campus. His work focuses on:

• Genomic data interpretation in cancer
• Precision medicine approaches to treatment selection
• Integration of molecular data with clinical decision-making

However, I don't have specific information in my knowledge base about Dr. [removed] particular expertise areas, publications, or clinical focus relevant to TP53-mutated AML/MDS. This is a gap I should acknowledge.

---

Why You Might Be Asking This Question

I suspect you're considering whether Dr. [removed] expertise in genomic interpretation and precision medicine might be relevant to this patient's complex genetic profile:

✅ Potentially relevant factors:

• TP53 Y220H mutation at high VAF (80-89%) - This is a specific, actionable mutation
• Complex karyotype with multiple deletions - Requires sophisticated genomic interpretation
• NF1 mutation co-occurrence - Adds another layer of molecular complexity
• Treatment resistance pattern - Multiple prior regimens with variable response

---

What NCCN Guidelines Say About TP53-Mutated AML

According to NCCN Guidelines for Acute Myeloid Leukemia (Version 2.2026), TP53 mutations carry critical prognostic weight:

TP53 mutations are classified as ADVERSE-RISK disease and are associated with:

• Poor outcomes with intensive chemotherapy
• Median overall survival of approximately 9 months (compared to 36 months for TP53 deletions)
• Higher frequency in patients ≥60 years of age
• Strong association with complex and monosomal karyotypes

The NCCN Guidelines note that "patients with TP53 mutations, particularly biallelic, have a poor prognosis even with transplantation. These cases should be discussed with a transplant physician and patients should be enrolled in a clinical trial whenever possible."

---

Clinical Relevance to THIS Patient

Your patient's profile suggests potential value in precision oncology consultation:

1) TP53-Specific Therapeutic Considerations

The TP53 Y220H mutation is a missense mutation (not a deletion). According to emerging research cited in NCCN guidelines, certain TP53 mutations may respond differently to specific agents:

• Ivosidenib or Olutasidenib (IDH1 inhibitors) - if IDH1 mutation present (not mentioned in your case)
• Venetoclax-based combinations - which this patient IS receiving
• Clinical trials targeting TP53-mutated AML - NCCN explicitly recommends this

2) Current Treatment Appropriateness

The patient is on Decitabine + Venetoclax, which aligns with NCCN recommendations for:

• Higher-risk MDS progressing to AML
• Patients who may not be candidates for intensive chemotherapy (age 69, comorbidities)

However, the recent blast reduction (19.6 → 3 x 10^9) could indicate:

• Early response to current regimen, OR
• Temporary cytoreduction before potential resistance

3) The Escalating Transfusion Requirement

The increasing platelet transfusion frequency (from baseline to every 1-3 days) is concerning and may indicate:

• Disease progression despite treatment
• Treatment-related myelosuppression
• Emerging chemotherapy resistance

---

What I Cannot Advise On (Honest Gaps)

I don't have specific information about:

1. Whether Dr. [removed] has particular expertise in TP53-mutated AML - You would need to verify his current research focus
2. Specific genomic interpretation services he may offer that could benefit this case
3. Clinical trial eligibility based on this patient's exact molecular profile
4. Emerging TP53-targeted therapies beyond what NCCN guidelines cover

---

What Your Care Team Should Consider

According to NCCN Guidelines, this patient warrants:

✅ Multidisciplinary discussion including:

• Hematologic malignancy specialist
• Transplant physician (for HCT evaluation despite poor prognosis)
• Precision oncology/genomics specialist (potentially someone like Dr. [removed] expertise area)
• Palliative care (given TP53 adverse-risk status)

✅ Clinical trial enrollment - NCCN explicitly states this is preferred for TP53-mutated AML

✅ Molecular tumor board review - To interpret the specific TP53 Y220H mutation and NF1 co-mutation in context of treatment options

---

Questions to Ask Your Oncology Team

1. "Has our team considered a precision oncology or genomics consultation to interpret the TP53 Y220H mutation specifically?"

2. "Are there clinical trials available for TP53-mutated AML that this patient might be eligible for?"

3. "Given the escalating transfusion requirements, should we reassess response to the current Decitabine + Venetoclax regimen?"

4. "What is the plan if the patient develops resistance to the current regimen?"

5. "Should we involve palliative care earlier given the TP53 adverse-risk classification?"

---

Summary

Sean Davis's relevance: His expertise in genomic interpretation and precision medicine could theoretically be valuable for this complex case, but I cannot confirm his specific focus on TP53-mutated AML without current information. This would be worth exploring with your care team.

What IS clear from NCCN Guidelines: This patient has adverse-risk disease requiring specialized multidisciplinary care, clinical trial consideration, and potentially genomics-informed treatment decisions.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.